Home/ Stocks/ GLUE

Monte Rosa Therapeutics, Inc. Common Stock

GLUE XNAS

$19.39 -0.42 (-2.12%) ▼ 15-min delayed

Open

$19.66

High

$20.11

Low

$19.16

Volume

547.1K

Market Cap

$1.64B

About Monte Rosa Therapeutics, Inc. Common Stock

Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).

Sector: BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) Employees: 150 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q3 2025	$12.77M	$-27,081,000	N/A
Q2 2025	$23.19M	$-12,295,000	N/A
Q1 2025	$84.93M	$46.88M	N/A
FY 2024	$75.62M	$-72,700,000	N/A

Earnings & Analyst Ratings

Next Earnings: Wed, Aug 5, 2026

Calendar →

Related Market News

No specific coverage for GLUE yet. Check out our latest market news or earnings calendar.

Get GLUE Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Monte Rosa Therapeutics, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.